Helping you see the full picture of coronary artery disease risk
Salix offers a high-accuracy and easy-to-use cardiovascular imaging solution that is unmatched in its scope of clinical metrics.
It speeds up screening for stenosis and other cardiovascular metrics to provide a more robust and comprehensive diagnosis and evaluation of cardiovascular risk. With an evidence base of thousands of scans, our AI-derived model overcomes the current challenges of cardiac imaging assessment and provides a more-complete picture of heart health.
Salix generates personalised high-quality anatomical images and interpretation. Patient reviews can be conducted within minutes – not hours – and the easy-to-read dashboard allows for rapid identification of high-risk individuals. This guides clinicians to deliver personalised therapeutic guidance and prevent potential complications.
In the cloud, Salix is secure and does not need software or downloads.
See the complete picture of cardiovascular health with Artrya Salix.
Based on leading coronary artery research
Our technology is based on cardiac-scan data from some of the world’s leading research institutes, including Canada’s University of Ottawa Heart Institute. Our team has a world-leading expert in vulnerable plaque cardiology, Professor Girish Dwivedi.
Comprehensive patient overview
Salix integrates three leading biomarkers for heart attack. It confirms the presence or absence, location and characterisation of high-risk vulnerable plaque, as well as calcium and stenosis. This provides a comprehensive picture of coronary artery disease risk at the point of care.
High accuracy coronary artery reports
Salix provided high-accuracy assessments and personalised cardiac reports in a 2021 Australian trial. It found >90 per cent accuracy for calcium, 90 per cent accuracy for stenosis >50 per cent, and >70 per cent accuracy for vulnerable plaque.
Regulatory-cleared cardiac imaging software
Salix has been cleared for Australian commercialisation and is included in the ARTG. Further international approvals are being sought. Salix complies with international medical device standards.
Research Publications Of Interest
Low-attenuation noncalcified plaque on coronary computed tomography angiography predicts myocardial infarction
The future risk of myocardial infarction is commonly assessed using cardiovascular risk scores, coronary artery calcium score, or coronary artery stenosis severity.
We assessed whether noncalcified low-attenuation plaque burden on coronary CT angiography (CCTA) might be a better predictor of the future risk of myocardial infarction.
Plaque burden, not coronary stenosis, linked to future events in stable CAD
Taking a broad view of atherosclerotic burden allows physicians to focus on stable patients at highest risk for future CVD.
Increasing plaque burden based on the coronary artery calcium (CAC) score and the presence of obstructive coronary artery disease on CT angiography are both associated with an increased risk of future cardiovascular events, but a new analysis suggests it’s the overall coronary plaque burden that appears to be the driving force behind patient risk.
Application of artificial intelligence in coronary computed tomography angiography
Recent studies and emerging data demonstrate feasibility of artificial intelligence-based high-level image analysis and interpretation tools that will likely enable medical practitioners to achieve more accurate diagnosis of coronary artery disease.
Emerging artificial intelligence-based computational modeling methods will assist with pre-operative planning for valve disease. Finally, early but significant work is also being performed in relation to real-time assessment of myocardial perfusion and fractional flow reserve using machine learning.
“Salix will enhance our ability to diagnose, report and also treat coronary artery disease. Ultimately, it would lead to more effective and personalised medical treatment.”
Harry Perkins Institute of Medical Research, Wesfarmers Chair in Cardiology - Professor Girish Dwivedi